109 related articles for article (PubMed ID: 16570574)
1. Expression of c-kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin.
Kung SP; Lee CH; Yang AH; Chi CW; Tseng LM; Wu CW
J Chin Med Assoc; 2006 Feb; 69(2):74-9. PubMed ID: 16570574
[TBL] [Abstract][Full Text] [Related]
2. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.
Fenton C; Patel A; Dinauer C; Robie DK; Tuttle RM; Francis GL
Thyroid; 2000 Apr; 10(4):349-57. PubMed ID: 10807064
[TBL] [Abstract][Full Text] [Related]
3. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
[TBL] [Abstract][Full Text] [Related]
4. Nitrotyrosine, inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) are increased in thyroid tumors from children and adolescents.
Patel A; Fenton C; Terrell R; Powers PA; Dinauer C; Tuttle RM; Francis GL
J Endocrinol Invest; 2002 Sep; 25(8):675-83. PubMed ID: 12240898
[TBL] [Abstract][Full Text] [Related]
5. Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma.
Zhao L; Zhu XY; Jiang R; Xu M; Wang N; Chen GG; Liu ZM
Int J Clin Exp Pathol; 2015; 8(9):11236-47. PubMed ID: 26617848
[TBL] [Abstract][Full Text] [Related]
6. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
Kim DS; Franklyn JA; Boelaert K; Eggo MC; Watkinson JC; McCabe CJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4603-11. PubMed ID: 16926250
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors.
Martins L; Matsuo SE; Ebina KN; Kulcsar MA; Friguglietti CU; Kimura ET
J Clin Endocrinol Metab; 2002 Oct; 87(10):4806-10. PubMed ID: 12364477
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor.
Ruggeri RM; Villari D; Simone A; Scarfi R; Attard M; Orlandi F; Barresi G; Trimarchi F; Trovato M; Benvenga S
J Endocrinol Invest; 2002 Dec; 25(11):959-66. PubMed ID: 12553555
[TBL] [Abstract][Full Text] [Related]
9. Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin-1 and angiogenic factors in human papillary thyroid carcinoma.
Donckier JE; Michel L; Delos M; Havaux X; Van Beneden R
Clin Endocrinol (Oxf); 2006 Jun; 64(6):703-10. PubMed ID: 16712675
[TBL] [Abstract][Full Text] [Related]
10. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents.
Patel A; Jhiang S; Dogra S; Terrell R; Powers PA; Fenton C; Dinauer CA; Tuttle RM; Francis GL
Pediatr Res; 2002 Nov; 52(5):737-44. PubMed ID: 12409522
[TBL] [Abstract][Full Text] [Related]
11. Detection of global hypermethylation in well-differentiated thyroid neoplasms by immunohistochemical (5-methylcytidine) analysis.
Keelawat S; Thorner PS; Shuangshoti S; Bychkov A; Kitkumthorn N; Rattanatanyong P; Boonyayothin W; Poumsuk U; Ruangvejvorachai P; Mutirangura A
J Endocrinol Invest; 2015 Jul; 38(7):725-32. PubMed ID: 25740063
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
13. Nuclear receptor expression in human differentiated thyroid tumors.
Mond M; Alexiadis M; Eriksson N; Davis MJ; Muscat GE; Fuller PJ; Gilfillan C
Thyroid; 2014 Jun; 24(6):1000-11. PubMed ID: 24559275
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus.
Hervé MA; Meduri G; Petit FG; Domet TS; Lazennec G; Mourah S; Perrot-Applanat M
J Endocrinol; 2006 Jan; 188(1):91-9. PubMed ID: 16394178
[TBL] [Abstract][Full Text] [Related]
15. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
[TBL] [Abstract][Full Text] [Related]
16. Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors.
Inan S; Vatansever S; Celik-Ozenci C; Sanci M; Dicle N; Demir R
Histol Histopathol; 2006 Oct; 21(10):1055-64. PubMed ID: 16835828
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas.
Fellmer PT; Sato K; Tanaka R; Okamoto T; Kato Y; Kobayashi M; Shibuya M; Obara T
Surgery; 1999 Dec; 126(6):1056-61; discussion 1061-2. PubMed ID: 10598188
[TBL] [Abstract][Full Text] [Related]
18. uPA receptor expression in benign and malignant thyroid tumors.
Kim SJ; Shiba E; Taguchi T; Tsukamoto F; Miyoshi Y; Tanji Y; Takai S; Noguchi S
Anticancer Res; 2002; 22(1A):387-93. PubMed ID: 12017319
[TBL] [Abstract][Full Text] [Related]
19. HLA-G is differentially expressed in thyroid tissues.
de Figueiredo Feitosa NL; Crispim JC; Zanetti BR; Magalhães PK; Soares CP; Soares EG; Neder L; Donadi EA; Maciel LM
Thyroid; 2014 Mar; 24(3):585-92. PubMed ID: 24089994
[TBL] [Abstract][Full Text] [Related]
20. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.
Pallares J; Rojo F; Iriarte J; Morote J; Armadans LI; de Torres I
Histol Histopathol; 2006 Aug; 21(8):857-65. PubMed ID: 16691538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
